Anti-microbial peptide hLF1-11 against infectious diseases (459 KB)
The antimicrobial peptide hLF1-11 comprises the first 11 N-terminal amino
acids of the endogenous protein; human lactoferrin. The compound exerts both
antibacterial and antifungal activity against a broad range of microorganisms.
Moreover, it appears that hLF1-11 has a low propensity to generate resistance
in microorganisms, because it acts by stimulating the innate immune system.
Overall safety has been established in preclinical and clinical studies and
efficacy at low systemic doses has been demonstrated in various infection models.
HLF1-11 exhibits in-vivo effects against a wide range of bacteria and fungi,
for example:
Bacteria:
Acetinobacter spp., E. coli, Salmonella spp., Klebsiella
pneumoniae, Pseudomonas auruginosae, Staphylococcus spp.
(including MRSA), Enterococcus faecales.
Fungi:
Candida spp. and Aspergillus fumigatus.
Anti-Microbial Peptide hLF1-11 to prevent infections during Hematopoietic Stem Cell Transplants
Around 70% of patients undergoing Hematopoietic Stem Cell Transplants (HSCT) suffer from potentially severe infections as complication. hLF1-11 is currently being tested for its ability to prevent infections in HSCT patients.
In the first part of this Phase IIa study, where one dose of hLF1-11 was given
to eight patients, no serious drug related safety issues hLF1-11 were encountered.
This study will be followed by a safety study in HSCT recipients receiving multiple
daily doses. After safety has been established a larger efficacy study may be
conducted in this patient population.
hLF1-11 for treatment of bacterial and fungal infections
AM-Pharma is planning two Proof of Concept Phase IIa studies in the following indications:
|
|
Anti-microbial peptide hLF1-11 against infectious diseases (459 KB) |